Investigating how DNA repeat silencing affects prostate cancer treatment with ATR inhibitors
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment
This study is looking at how certain changes in the DNA of advanced prostate cancer cells can make them more responsive to a new type of treatment called ATR inhibitors, with the goal of finding better ways to help patients with hard-to-treat prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11059841 on NIH RePORTER |
What this research studies
This research explores the role of DNA repeat silencing in enhancing the effectiveness of ATR inhibitors (ATRi) for treating advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC). The study aims to understand how certain genetic changes in cancer cells can increase their sensitivity to ATRi by promoting the transcription of specific DNA sequences. By examining the impact of these alterations, the research seeks to identify potential strategies to improve treatment outcomes for patients with advanced prostate cancer. Patients may be involved in trials that assess the effectiveness of these new treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with advanced prostate cancer, especially those with castration-resistant forms of the disease.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with ATR inhibitors in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Brown, Eric J — University of Pennsylvania
- Study coordinator: Brown, Eric J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.